Cd79a jcb117

Manufactured by Agilent Technologies

Sourced in Denmark

CD79a (JCB117) is a laboratory instrument used for the detection and analysis of the CD79a protein. CD79a is a component of the B-cell antigen receptor complex and plays a crucial role in B-cell development and activation. The instrument allows for the identification and quantification of CD79a in various biological samples.

Automatically generated - may contain errors

Lab products found in correlation

Bcl2 124, by Agilent Technologies (2 mentions) Sp4 r, by Roche (1 mentions) Mib 1, by Agilent Technologies (1 mentions) Cd10 56c6, by Leica (1 mentions) Cd20 l26, by Leica (1 mentions) Cd3 polyclonal, by Agilent Technologies (1 mentions) Mum1p, by Agilent Technologies (1 mentions) Eber probe, by Leica (1 mentions) Myc y69, by Abcam (1 mentions) Cd30 ber h2, by Agilent Technologies (1 mentions) Cd5 4c7, by Leica (1 mentions) Ki 67 mib 1, by Agilent Technologies (1 mentions) Progres c10plus, by Jenoptik (1 mentions) Axio imager a1, by Zeiss (1 mentions) Automated immunostainer, by Roche (1 mentions) B220 ra3 6b2, by BD (1 mentions)

Spelling variants of this product

CD79a (11 citations) CD79a (clone JCB117, (3 citations) JCB117 (2 citations)

3 protocols using cd79a jcb117

Immunohistochemical Evaluation of B-Cell Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

The B‐cell lymphoma diagnosis was made according to the 2017 WHO classification. Two hematopathologists reviewed the BM slides for the histopathological detection of BMI. Immunohistochemical staining was performed using monoclonal antibodies against the following antigens: CD3 (polyclonal, 1:200; Dako), CD5 (SP19, RTU; Roche), CD10 (56C6, 1:200; Novocastra), CD20 (L26, 1:4; Novocastra), CD79a (JCB117, 1:200; Dako), BCL2 (124, 1:200; Dako), BCL6 (GI191E/A8, RTU; Roche), cyclin D1 (SP4‐R, RTU; Roche), FMC7 (4C7, 1:100; Novocastra), Ki‐67 (MIB‐1, 1:100; Dako), and MUM‐1 (MUM1p, 1:400; Dako).

Jeon M.J., Yu E.S., Kim D.S., Choi C.W., Kim H.N., Kwon J.A., Yoon S, & Yoon J. (2024). Assessment of Bone Marrow Involvement in B‐Cell non‐Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next‐Generation Sequencing. Journal of Clinical Laboratory Analysis, 38(6), e25027.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Lymphoid Neoplasms

Check if the same lab product or an alternative is used in the 5 most similar protocols

Pathological specimens were fixed in 10% neutral buffered formalin, embedded in paraffin, and then subjected to histopathological examination. The monoclonal antibodies used for immunohistochemistry (IHC) were: anti-CD3 (PS1; Nichirei Biosciences), CD5 (4C7; Leica Biosystems, Newcastle upon Tyne, UK), CD10 (56C6; Leica Biosystems), CD20 (L26; Leica Biosystems), CD30 (Ber-H2; DAKO, Glostrup, Denmark), CD79a (JCB117; DAKO), BCL2 (124; DAKO), BCL6 (LN22; Nichirei Biosciences), MUM1 (NCL-L-MUM1; Leica Biosystems), Ki-67 (MIB-1; DAKO), MYC (Y69; Abcam PLC, Cambridge, UK), BCL3 (clone 1E8; Novocastra, Newcastle upon Tyne, UK), and PD-1 (NAT105; Abcam). Insitu hybridization (ISH) for Epstein-Barr virus (EBV)-encoded RNA (EBER) was performed using EBER Probe (Leica Biosystems) according to the manufacturer’s instructions.

Ohno H., Maekawa F., Hayashida M., Nakagawa M., Fukutsuka K., Matsumura M., Takeoka K., Maruyama W., Ukyo N., Sumiyoshi S., Tanaka Y, & Haga H. (2024). Diverse B-cell tumors associated with t(14;19)(q32;q13)/IGH::BCL3 identified by G-banding and fluorescence in situ hybridization. Journal of Clinical and Experimental Hematopathology : JCEH, 64(1), 21-31.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Organ Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

All organs were fixed in 4% formalin and embedded in paraffin. For histology, 3–5-µm-thick sections were cut and stained with haematoxylin and eosin (H&E). Immunohistochemistry was performed on an automated immunostainer (Ventana Medical Systems, Tucson, AZ, USA) according to the company’s protocols for open procedures. The slides were stained with the following antibodies: CD3 (SP7, 1:400) (DCS Innovative Diagnostik-Systeme GmbH u. Co. KG), B220 (RA3-6B2, 1:50) (BD), CD79a (JCB117, 1:50) (DakoCytomation) and Ki-67 (SP6, 1:100) (DCS Innovative Diagnostik-Systeme GmbH u. Co. KG) and LCK (Cell Signalling, 1:100). Appropriate positive and negative controls were used to confirm the adequacy of the staining. Pictures were taken with the Axio Imager A1 (Zeiss) and the ProgRes^® C10plus (JenOptik) camera and analysed with ImageAccess 6 Release 07.4 (Imagic Bildverarbeitungs AG).

Märklin M., Heitmann J.S., Fuchs A.R., Truckenmüller F.M., Gutknecht M., Bugl S., Saur S.J., Lazarus J., Kohlhofer U., Quintanilla-Martinez L., Rammensee H.G., Salih H.R., Kopp H.G., Haap M., Kirschniak A., Kanz L., Rao A., Wirths S, & Müller M.R. (2017). NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia. Nature Communications, 8, 755.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!